News
US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on
Charles River Laboratories To Participate In Barclays Global Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will participate in the Barclays Global Healthcare Conference. The Company will present on Wednesday, March 11th
Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration
Regulatory News:
Curadigm, an early-stage nanotechnology company committed to improving treatment outcomes by redefining the therapeutic balance between bioavailability, toxicity, and efficacy
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and year ended December 31, 2019. Amounts, unless
Savara to Report Fourth Quarter/Year-End 2019 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report fourth quarter/year-end 2019 financial results and provide a business update on Thursday
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on
Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on
Charles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Nancy C. Andrews, M.D., Ph.D., to its Board of Directors, effective February 28, 2020. Dr. Andrews is
Navidea Biopharmaceuticals to Host Fourth Quarter 2019 Earnings Conference Call and Corporate Update
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Susan Hockfield Elected to Pfizer’s Board of Directors
Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Hockfield to its Board of Directors, effective immediately. Dr. Hockfield, age 68, was also appointed to the Regulatory and
Biofrontera: Kleiner, aber feiner Geldregen
Die Biofrontera-Aktie (WKN: 604611) gehört am Dienstag zu den stärksten Werten. Im Xetra-Handel schließt der Kurs +16,10% höher bei 4,65 Euro. Das hat einen guten Grund.
Das Biopharma-Unternehmen
Qiagen: Heiße Übernahme-Wette geht auf
Ungeahnte Freudensprünge bei Qiagen (WKN: A2DKCH): Weil jetzt doch noch ein Übernahmeangebot kommt, gewinnt die Aktie heute um rund 18 Prozent auf 37,5 Euro – der größte Tageszuwachs seit zwei
ICON plc to Present at Barclays Global Healthcare Conference 2020
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr
Clovis Oncology to Present at the Barclays Global Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Barclays Global Healthcare Conference on Tuesday, March
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and full year 2019 financial results on Thursday, March 5, 2020, after
Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB
GenSight Biologics Announces Presentation of Bilateral Visual Recovery From GS010 (LUMEVOQ™) Phase III Trials at the 46th Annual Meeting of NANOS
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
Vifor Pharma Secures a Second Investment Grade Rating From Fitch Ratings
Regulatory News:
Vifor Pharma today announced that Fitch Ratings (Fitch) has initiated coverage of Vifor Pharma with an investment grade BBB- credit rating and a stable outlook. This investment
Takeda schließt Verkauf ausgewählter OTC- und nicht zum Kerngeschäft gehörender Assets an Acino ab
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) meldete heute den Abschluss des bereits angekündigten Verkaufs eines Portfolios ausgewählter, frei verkäuflicher
Heat Biologics mit +210% in 2 Tagen – dank Corona!
Als einer der meistdiskutierten Werte in unserem Live Chat macht die Aktie von Heat Biologics (WKN: A2JB4Y) aktuell mit einem Höhenflug von +210% innerhalb von nur zwei Tagen auf sich aufmerksam
Takeda vereinbart Veräußerung ausgewählter kernferner und OTC-Aktiva in Lateinamerika an Hypera Pharma für 825 Mio. USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) hat eine Vereinbarung darüber geschlossen, ein Portfolio ausgewählter kernferner Produkte ausschließlich für den
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
-
Cowen 40th Annual Health Care
QIAGEN Announces 20-F Annual Report Filing for 2019 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended